Preeclampsia Therapeutics Market

The antihypertensives segment leads the preeclampsia therapeutics market by drug class with a 43.4% share in 2026. Mild preeclampsia accounts for 42.9% by severity, while prophylaxis holds the largest treatment setting share at 53.3%.